Point72 Hong Kong’s Terns Pharmaceuticals TERN Stock Holding History

Point72 Hong Kong’s Portfolio TERN Stock Details TERN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-71	Closed	–	–	2395
2022 Q1	$0	Buy	+71	New	+$303	﹤0.01%	2310

Other funds holding TERN

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Antara Capital New York $30.2K AUM 5.24% 1-Year Est. Return

Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Point72 Asset Management

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Point72 Hong Kong's TERN Position: Q2 2022 in Review

Point72 Hong Kong sold out of Terns Pharmaceuticals (TERN) in Q2 2022, closing a stake of 71 shares.

Point72 Hong Kong first reported a position in TERN in Q1 2022 and held it in 1 quarter. The position peaked at $0 in Q1 2022. 42 funds tracked by Wall St. Rank hold TERN as of Q2 2022.

Point72 Hong Kong reported no remaining Terns Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
Point72 Hong Kong sold 71 Terns Pharmaceuticals shares in Q2 2022.
Point72 Hong Kong first reported a position in Terns Pharmaceuticals in Q1 2022 and held it in 1 quarter.
Point72 Hong Kong's Terns Pharmaceuticals position peaked at $0 in Q1 2022.
42 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q2 2022.

Based on Point72 Hong Kong's 13F filing for Q2 2022, filed 15 Aug 2022.